DBV Technologies S.A.

Good afternoon and welcome to the DBV Technology Second Quarter Financial Results Conference Call. My name is Vaishnavi and I am the operator for this call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal for a conference specialist by pressing star and zero. Following the formal remarks, we will open up the call for your questions. Please be advised that this call is being recorded at the company's request time. and now I'd like to turn it over to Katie Matthews, Head of Investor Relations. Katie, please go ahead.

Thank you. This afternoon, DBV Technologies issued a press release that outlined our financial results for the three and six months ended June 30th, 2023. This press release is available in the Press Releases section of the DBV Technologies website. Before we begin, please note that today's call may include a number of forward-looking statements, including but not limited to comments regarding our clinical and regulatory development plans, the design of our anticipated clinical trials, the timing and results of interactions with regulatory agencies, our forecast of our cash runway, and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Please refer to the company's filings with the SEC and the French AMF for information concerning risk factors that could cause the company's actual results to differ materially from expectations, including any forward-looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call. Joining me on the call today are Daniel Tassé, Chief Executive Officer of DBV, Dr. Pharis Mohideen, Chief Medical Officer, and Sebastian Robitaille, Chief Financial Officer. I will now pass the call over to Daniel. Daniel.

Katie, thank you. And thank you all for joining us on this call today. The purpose of this call today is twofold. One, to provide a business update on our two Bias Skin Peanut programs, including feedback we received recently from the FDA through a Type C meeting on our two pending supplemental safety studies, one in toddlers, one in children, and secondly, to review DBV's financial highlights for the first half of 2023. Now let me summarize what I think has been well established regarding our two via skin peanut development programs before turning the call over to Pharis for an update on recent FDA exchanges and next steps in our clinical and regulatory work. As you know, DBV is advancing in parallel to clinical programs for via skin peanut, via skin peanut in toddlers age one to three, and Viaskin, Peanut and Children aged 4 to 7. It's important to recognize that Viaskin, Peanut and 1 to 3-year-olds and Viaskin, Peanut and 4 to 7-year-olds are separate product candidates with independent clinical and regulatory paths that we believe will ultimately support two distinct BLAs. With that being said, as a reminder, let me pass the call on to Pharis. We'll share with you More details.